Latest Data Shows OrbusNeich's COMBO(TM) Dual Therapy Stent has Excellent Healing Benefits

Washington (ots/PRNewswire) -

The world's first and only dual therapy stent

Prof. Stephen W.L. Lee presented two-year optical coherence
tomography (OCT) findings and three-year clinical follow up from the
EGO COMBO study, providing further evidence to support the healing
benefits of the COMBO Dual Therapy Stent, the only drug eluting stent
(DES) with active EPC capture technology.

The findings were presented during the 26th Annual Transcatheter
Cardiovascular Therapeutics (TCT) meeting, held in Washington, D.C.,
September 13-17, 2014.

"This is the first study to assess the healing profile of a dual
therapy stent by optical coherence tomography," said Prof. Stephen
W.L. Lee, M.D., of the Queen Mary Hospital, Hong Kong. "The COMBO
Stent's unique approach shows early healing benefits and stability
over the long-term. The results demonstrate no neoatherosclerosis
observed by OCT at 24 months, and no late restenosis or stent
thrombosis beyond 36 months. The COMBO Stent is the only DES which
exhibits neointima regression from 9 months to 24 months. This is an
indication of true vessel healing."

Latest evidence surrounding the COMBO Stent's active EPC capture
was also presented by Prof. Michael Haude, M.D., Lukaskrankenhaus,
Neuss, Germany, and President-Elect of the EAPCI, who demonstrated
how the COMBO Stent uses a bound antibody to capture EPCs and
promotes accelerated endothelial coverage.

"The COMBO Stent sets a new standard for stenting," said Prof.
Haude. "With the dual therapy approach of the COMBO Stent, the
abluminal sirolimus release from a bioresorbable polymer matrix
controls the restenosis and neointimal proliferation, whilst the
luminal surface is coated with an antibody that enables an earlier
and more mature healing of the stented lesion. Delayed healing is of
continued concern in conventional DES today as it leads to stent
thrombosis and, in the long-term, to neoatherosclerosis. The COMBO
Stent helps to address these concerns and may offer a long-term
solution."

About the COMBO Dual Therapy Stent

The COMBO Dual Therapy Stent is the first dual therapy stent to
both accelerate endothelial coverage and control neo-intimal
proliferation through the combination of the proven Pro-Healing
Technology with an abluminal sirolimus drug elution delivered from a
biodegradable polymer that is completely dissipated within 90 days.

OrbusNeich's patented endothelial progenitor cell (EPC) capture
technology promotes the accelerated natural healing of the vessel
wall after the implantation of blood-contact devices such as stents.
The technology consists of an antibody surface coating that captures
EPCs circulating in the blood to the device to form an endothelial
layer that provides protection against thrombosis and modulates
restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops,
manufactures and markets innovative medical devices for the treatment
of vascular diseases. Current products are the world's first dual
therapy stent, the COMBO Dual Therapy Stent, and the world's first
pro-healing stent, the Genous(TM) Stent. Other products include
stents and balloons marketed under the names of Azule(TM), R
Stent(TM), Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC.
OrbusNeich is headquartered in Hong Kong and has operations in
Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands;
and Tokyo, Japan. OrbusNeich supplies medical devices to
interventional cardiologists in more than 60 countries. For more
information, visit http://www.OrbusNeich.com.

Follow OrbusNeich on Twitter at http://www.twitter.com/OrbusNeich,
and learn more about the company and its innovative technology on
OrbusNeich's YouTube Channel:
http://www.youtube.com/user/OrbusNeichMedia.

ots Originaltext: OrbusNeich
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Global Media Contacts: Cheryl Pitcher, +44(0)78-09-492-191,
cheryl.pitcher@fleishmaneurope.com, Iva Ng, OrbusNeich,
+852-3109-7268,
ing@orbusneich.com